Study examined the long term side effects of the combination of bortezomib, bendamustine and rituximab for first line treatment of follicular lymphoma.
Home / Resource Library / A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408